The U.S. Food and Drug Administration (FDA) approves a new drug to treat kidney cancer.

The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., can help curb the size and number of tumors in the most common form of kidney cancer, but has yet to make an impact on the length of life of the patients

Kraft Foods Inc. announced Tuesday that it has completed its mulit-year, voluntary effort to reduce trans-fat in its products.

Kraft has significantly reformulated seven product categories including cereal, cookies, crackers, pizza, desserts, meals and Oscar Mayer, reports MarketWatch

In a move to make popcorn snacking healthier, Orville Redenbacher and ACT II microwave popcorn brands plan to change their recipe.

By February, almost all the different popcorn products made by Omaha-based ConAgra Foods Inc. will be free of trans fatty acids, which contribute to higher levels of LDL cholesterol and can increase the risk of heart disease

An experimental vaccine has been put to the test by U.S. students in Mexico and Guatemala to cure traveler's diarrhea, scientists reported Friday.

The vaccine is an important development as scientist have long thought that advising travelers to avoid risky food and water was the only way to avoid the germs that cause traveler's diarrhea. The research proves that the use of a vaccine can be effective. ''This is a very encouraging first step,'' said microbiologist A. Louis Bourgeois of Johns Hopkins University's Bloomberg School of Public Health, who led the study of the Swedish-developed vaccine

An experimental vaccine has been put to the test by U.S. students in Mexico and Guatemala to cure traveler's diarrhea, scientists reported Friday.

The vaccine is an important development as scientist have long thought that advising travelers to avoid risky food and water was the only way to avoid the germs that cause traveler's diarrhea. The research proves that the use of a vaccine can be effective. ''This is a very encouraging first step,'' said microbiologist A. Louis Bourgeois of Johns Hopkins University's Bloomberg School of Public Health, who led the study of the Swedish-developed vaccine